Range of inactivated vaccines to control and prevent bluetongue virus disease (Serotypes 1, 4 and 8).
A TOOL FOR PREVENTION
BLUEVAC BTV is key to control Bluetongue virus (serotypes 1, 4 and 8) in sheep and cattle. The active immunization obtained is essential to tackle the geographic spread of the disease.
It prevents the viraemia of serotypes 1, 4 and 8. Tested and validated by using RT-PCR, BLUEVAC BTV prevents viraemia, which means there is no presence of viral genome after vaccination.
ADVANCED ADJUVANT TECHNOLOGY
BLUEVAC BTV is based on the use of aluminum hydroxide and Quil A as adjuvants. Quil A is a derivative of purified saponin that blocks viral antigens and slows them, so they are captured by immune cells in vaccinated animals.
FEWER LOCAL REACTIONS
The use of the Quil A purified saponin as an adjuvant produces no serious local reactions.
- Controls out break of clinical cases of bluetongue disease
- Cost-benefit of one dose vs losses due to clinical signs, decreased production and decreased fertility
- Control over spread of the disease and declining trade restrictions
More than 230 million doses of BLUEVAC BTV administered in Europe have shown that vaccination with BLUEVAC is a valuable method and the best choice to reduce clinical signs and viraemia in sheep and cattle herds.
DECREASES THE PREVALENCE OF BLUETONGUE
Vaccination with BLUEVAC BTV prevents viraemia and transmission to healthy animals, decreasing the prevalence of the disease in endemic areas.
With a collapsible plastic bottle, BLUEVAC BTV packaging is stronger and lighter, and does not require vented draw-off equipment.